Jeremic 1997.
Methods | Prospective randomized trial, open‐label Inclusion criteria
Exclusion criteria
|
|
Participants | E arm: 59 participants/22 participants ≥ 60 years/number of elderly participants not informed CE arm: 58 participants/18 participants ≥ 60 years/number of elderly participants not informed |
|
Interventions | E arm: etoposide 50 mg/m2/d p.o. on days 1 through 21 every 28 days CE arm: carboplatin 400 mg/m2 over 30‐minute i.v. infusion on day 1 and etoposide 50 mg/m2/d p.o. on days 1 through 21 every 28 days |
|
Outcomes | Response rate (according to WHO response criteria) Toxicity according to ECOG criteria Overall survival |
|
Notes | Study prematurely interrupted because chief investigator left the department | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | No information on random sequence generation |
Allocation concealment (selection bias) | Unclear risk | No information on allocation concealment |
Blinding of outcome assessment (detection bias) OS and 1y OS rate outcome | Unclear risk | No information on blinding of outcome assessment for OS |
Blinding of outcome assessment (detection bias) Other outcomes | Unclear risk | No information on blinding of outcome assessment for PFS, ORR, and toxicity |
Incomplete outcome data (attrition bias) All outcomes | Low risk | No evidence of attrition bias |
Selective reporting (reporting bias) | Low risk | No evidence of reporting bias |
Other bias | High risk | Trial prematurely stopped because of personnel problems (chief investigator had to leave department). No information provided for elderly subgroup |